AF
FULC icon

Allworth Financial’s Fulcrum Therapeutics FULC Stock Holding History

Allworth Financial’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.62K Buy
+863
New +$8.01K ﹤0.01% 3784
2022
Q4 		– Sell
-65
Closed -$1K – 3074
2022
Q3 		$1K Buy
+65
New +$465 ﹤0.01% 2377

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Allworth Financial's FULC Position: Q1 2026 in Review

Allworth Financial opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 863 shares worth $6.62K. The stake represents ﹤0.01% of the portfolio and ranks #3784 among its holdings. This is a return to the name: Allworth Financial previously reported a position in FULC as recently as Q3 2022.

Allworth Financial first reported a position in FULC in Q3 2022 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Allworth Financial held 863 shares of Fulcrum Therapeutics worth $6.62K as of Q1 2026.
  • Fulcrum Therapeutics was a new Allworth Financial position in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #3784 holding.
  • Allworth Financial first reported a position in Fulcrum Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.